



 **Chiesi**  
Global Rare Diseases 

**CHIESI RARE DISEASES.  
OUR COMMITMENT, YOUR EMPOWERMENT.**

WHAT BEGAN AS A DREAM NOW AIMS  
TO REVOLUTIONIZE PATIENTS' LIVES.

# 85


## YEARS OF RESEARCH & INNOVATION IN OUR DNA.<sup>1</sup>

Founded over 85 years ago, Chiesi is a family-controlled, Italian pharmaceutical company that now employs over 5,500 people and has a global presence.<sup>1</sup>

### CHIESI IN THE WORLD<sup>1,2</sup>



In 2019 the Chiesi Group launched Rare Diseases, a business unit that works in collaboration with other functions of the Chiesi Group while maintaining an exclusive focus to develop and commercialize products that help to address the unique needs of patients with rare diseases.



## **EACH LIFE IS RARE. AND WE ARE COMMITTED TO THE RAREST ONES.**

Patients have been at the center of what we do for decades.

We believe that no patient should be left behind, which is why we decided to create a business unit specifically dedicated to those with rare diseases.

Patients with rare diseases can encounter many difficulties, from getting a timely and accurate diagnosis, to accessing effective medical and social care, resulting in a heavy burden on patients.<sup>3</sup>

As such, we believe this therapeutic area to be of great importance and impact.

By 2025, we aspire to be a point of reference for patients affected by rare diseases.

We commit to offer patients, and those who take care of them, innovative solutions in the management of their needs, exploring new frontiers in treatment and care.<sup>1</sup>

# Chiesi Rare Diseases is specifically committed to these key areas:



## LYSOSOMAL STORAGE DISORDERS<sup>4</sup>

- Fabry disease
- Alpha-mannosidosis
- Nephropathic cystinosis



## RARE HEMATOLOGIC DISORDERS

- Beta thalassemia



## RARE OPHTHALMOLOGIC DISORDERS

- Leber's hereditary optic neuropathy (LHON)



## Investments in research and development:

**1<sup>st</sup>** among Italian pharmaceutical companies\*

**2<sup>nd</sup>** among Italian manufacturing companies\*

**13<sup>th</sup>** among European pharmaceutical companies\*



## CHIESI IS THE LARGEST GLOBAL PHARMACEUTICAL GROUP TO BE AWARDED B CORP CERTIFICATION.<sup>1</sup>



Certified Benefit Corporations (B Corps) are for-profit companies that use the power of business to build a more inclusive and sustainable economy.

They meet the highest verified standards of social and environmental performance, transparency, and accountability.

B Corps are the expression of a more evolved vision and incorporate a two-fold purpose into their business objectives: in addition to the objective of generating profit, they also pursue the goal of making a positive impact on society and the environment and undertake to create value not only for shareholders but also for the other stakeholders.<sup>1</sup>

*Let's make  
the world  
feel better.*

Chiesi's decision to become a certified B Corp represents our commitment to join a growing movement of for-profit companies determined to create a significant positive impact on our patients, people, shareholders, suppliers, communities and the environment we operate in.

Chiesi strives for ethical accountability and acting as a force for good, which is why we believe that:<sup>1</sup>

- Principles should be based on creating a positive impact on nature and society
- Resources should be handled in a sustainable way
- A purpose should be defined beyond purely profit, for a broader, collective benefit

# CHIESI RARE DISEASES. OUR COMMITMENT, YOUR EMPOWERMENT.

COURAGE

HERITAGE & INNOVATION

PASSION

1. Chiesi 2018 Annual Report. Available at : [https://www.chiesi.com/flipbook.php?url=https://www.chiesi.com/img/annual\\_report/documenti/29\\_annual-report-2018-\\_english.pdf](https://www.chiesi.com/flipbook.php?url=https://www.chiesi.com/img/annual_report/documenti/29_annual-report-2018-_english.pdf). Last accessed: December 19, 2019.
2. Chiesi USA. About us. Available at: <https://www.chiesiusa.com/about-us/#>. Last accessed: December 19, 2019.
3. Chiesi. Rare Diseases. Available at: <https://www.chiesi.com/en/therapeutic-areas/rare-diseases/#>. Last accessed: December 19, 2019.
4. Gainotti S, et al., International Journal of Environmental Research and Public Health 2018; 15(10): 2072.

Cod.RD\_19\_007  
Date of preparation: December 2019  
CHIESI Farmaceutici S.p.A.  
Via Palermo, 26/A - 43122 Parma Italy  
Tel. +39 0521 2791  
[info@chiesi.com](mailto:info@chiesi.com) - [www.chiesi.com](http://www.chiesi.com)



 **Chiesi**  
Global Rare Diseases 